Home >> Research Area >> Roxithromycin

Roxithromycin

CAS# 80214-83-1

Roxithromycin

2D Structure

Catalog No. BCC4842----Order now to get a substantial discount!

Product Name & Size Price Stock
Roxithromycin: 5mg $12 In Stock
Roxithromycin: 10mg Please Inquire In Stock
Roxithromycin: 20mg Please Inquire Please Inquire
Roxithromycin: 50mg Please Inquire Please Inquire
Roxithromycin: 100mg Please Inquire Please Inquire
Roxithromycin: 200mg Please Inquire Please Inquire
Roxithromycin: 500mg Please Inquire Please Inquire
Roxithromycin: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Roxithromycin

3D structure

Package In Stock

Roxithromycin

Number of papers citing our products

Chemical Properties of Roxithromycin

Cas No. 80214-83-1 SDF Download SDF
PubChem ID 9567573 Appearance Powder
Formula C41H76N2O15 M.Wt 837.06727
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (119.47 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
SMILES CCC1C(C(C(C(=NOCOCCOC)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O
Standard InChIKey RXZBMPWDPOLZGW-KMAKEOJNSA-N
Standard InChI InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23?,24+,25+,26-,27?,28?,29-,30?,32?,33+,34-,35?,36-,38?,39-,40?,41-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Roxithromycin

DescriptionRoxithromycin is a semi-synthetic macrolide antibiotic. Target: Antibacterial Roxithromycin is a semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue infections. Roxithromycin is derived from erythromycin, containing the same 14-membered lactone ring. Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. From Wikipedia.

References:
[1]. http://en.wikipedia.org/wiki/Roxithromycin

Roxithromycin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Roxithromycin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Roxithromycin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.1946 mL 5.9732 mL 11.9465 mL 23.8929 mL 29.8662 mL
5 mM 0.2389 mL 1.1946 mL 2.3893 mL 4.7786 mL 5.9732 mL
10 mM 0.1195 mL 0.5973 mL 1.1946 mL 2.3893 mL 2.9866 mL
50 mM 0.0239 mL 0.1195 mL 0.2389 mL 0.4779 mL 0.5973 mL
100 mM 0.0119 mL 0.0597 mL 0.1195 mL 0.2389 mL 0.2987 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Roxithromycin

Roxithromycin

Featured Products
New Products
 

References on Roxithromycin

Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.[Pubmed:28039274]

J Antimicrob Chemother. 2017 Apr 1;72(4):1129-1136.

Objectives: The macrolide antibiotic Roxithromycin has seen widespread clinical use for several decades; however, no population pharmacokinetic analysis has been published. Early studies indicated saturation of protein binding and absorption at doses within the approved range, which may impact pharmacodynamic target attainment since regimens of 150 mg twice daily and 300 mg once daily are used interchangeably in clinical practice. This study aimed to develop a population-based meta-analysis of Roxithromycin pharmacokinetics, and utilize this model to inform optimal dosing regimens. Methods: Following an extensive search, Roxithromycin pharmacokinetic data were collected or digitized from literature publications. Population pharmacokinetic modelling was undertaken with ADAPT. Dosing simulations were performed to investigate differences in exposure and pharmacodynamic target attainment between dosing regimens. Results: A two-compartment model with saturable absorption described the data ( n = 63); changes in free drug exposure were simulated using a saturable protein binding model. Simulations indicated that a 300 mg daily regimen achieves a 37% and 53% lower total or free AUC ( f AUC), respectively, compared with 150 mg twice daily. These pharmacokinetic differences translated to significantly lower target attainment ( f AUC/MIC ratio >20) with a 300 mg daily regimen at MICs of 0.5 and 1 mg/L (51% and 7%) compared with patients receiving 150 mg twice daily (82% and 54%). Conclusions: Roxithromycin displays saturable absorption and protein binding leading to lower exposure and lower target attainment at MICs >/=0.5 mg/L with widely used once-daily dosing regimens, indicating that twice-daily regimens may be preferable for pathogens less susceptible to Roxithromycin.

Topical delivery of roxithromycin solid-state forms entrapped in vesicles.[Pubmed:28119103]

Eur J Pharm Biopharm. 2017 May;114:96-107.

Recently, considerable interest developed in using newer/improved antibiotics for the treatment of Acne vulgaris. During this study, different Roxithromycin solid-state forms (i.e. crystalline and amorphous) were encapsulated into vesicle systems (niosomes, proniosomes, ufosomes and pro-ufosomes) for dermis targeted delivery. Characterization of the vesicles was done with transmission electron microscopy, light microscopy, droplet size, droplet size distribution, pH, zeta-potential and entrapment efficiency percentage. Finally, comparative release and topical diffusion studies were performed, to evaluate if targeted topical delivery was obtained and if the Roxithromycin solid-state amorphous forms resulted in improved topical delivery. Vesicle systems containing different Roxithromycin (2%) solid-state forms were successfully prepared and characterized. The vesicles showed optimal properties for topical delivery. All carrier systems had topical delivery to the epidermis-dermis, whilst no Roxithromycin was found in the receptor compartment or stratum corneum-epidermis. The niosomes were the leading formulation and the two amorphous forms had better topical delivery than the crystalline form. Successful targeted delivery of Roxithromycin was obtained in the dermis, where the activity against Propionibacterium acnes is needed. The amorphous forms seemed to have held their solid-state form during formulation and in the vesicles, showing improved topical delivery in comparison to the crystalline form.

Description

Roxithromycin (RU-28965) is a semi-synthetic macrolide antibiotic.

Keywords:

Roxithromycin,80214-83-1,Natural Products, buy Roxithromycin , Roxithromycin supplier , purchase Roxithromycin , Roxithromycin cost , Roxithromycin manufacturer , order Roxithromycin , high purity Roxithromycin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: